+ 12,3 % bei Geron (902213) Was ist los? o. T.

 

Zahlen für Q2/21

• keine Umsätze
  
• Verlust 30 Mio. $
  
• Cash 239 Mio. $
  
• MK 405 Mio. $
  

These financial resources, combined with expected future non-dilutive funding under the current debt facility, are now expected to fund operations through the end of the first quarter of 2023.

“We are pleased with the achievement of 91% of the planned enrollment in IMerge Phase 3 and expect the trial to be fully enrolled in the fourth quarter of 2021. In addition, the expected timing for top-line results in IMerge Phase 3 has been accelerated by three months to the first quarter of 2023,”

https://ir.geron.com/investors/press-releases/...of-2023/default.aspx

 

Publication of Analyses Comparing Real World Data to IMbark Phase 2 in Annals of Hematology

•Analyses Suggest Survival Benefit Associated with Imetelstat Treatment in Comparison to Best Available Therapy

•Overall Survival is Primary Endpoint for Ongoing Phase 3 Clinical Trial in Refractory MF


https://ir.geron.com/investors/press-releases/...atology/default.aspx
 

Zahlen für Q3/21

• kein Umsatz
  
• Verlust 27 Mio. $
  
• Cash 176 Mio. $
  
• MK 328 Mio. $
  

https://d18rn0p25nwr6d.cloudfront.net/...4835-9fc7-6576fce03f8c.html#

 

Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants

https://finance.yahoo.com/news/...nces-proposed-public-200100969.html

Und wir sind schon bei 323.73M outstanding shares.  

…today announced the pricing of its previously announced underwritten public offering of 53,333,334 shares of its common stock and pre-funded warrants to purchase 18,095,238 shares of its common stock, together with accompanying warrants to purchase 35,714,286 shares of its common stock. The combined offering price to the public of each share of common stock and accompanying warrant is $1.05. The combined offering price to the public of each pre-funded warrant and accompanying warrant is $1.049. The common stock and pre-funded warrants will be sold in combination with an accompanying warrant to purchase 0.5 of a share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $1.45 per share and expires five years from the date of issuance; however, such term will be shortened upon achievement of a regulatory milestone.

All of the securities in the offering are being sold by Geron. The gross proceeds to Geron from this underwritten public offering are expected to be approximately $75.0 million, before deducting the underwriting discount and other estimated offering expenses payable by Geron. The offering is expected to close on or about April 1, 2022, subject to the satisfaction of customary closing conditions.

Geron currently intends to use the net proceeds from this public offering, together with its existing cash, cash equivalents, restricted cash and marketable securities to fund potential regulatory filings in the United States and European Union for imetelstat in lower risk myelodysplastic syndromes (MDS), assuming top-line results in the IMerge Phase 3 clinical trial are supportive, and to support toward the completion of the IMpactMF clinical trial in refractory myelofibrosis and the planned exploratory studies in new indications, including IMproveMF and investigator-led trials in acute myeloid leukemia and higher risk MDS, the preclinical work in lymphoid malignancies and the discovery research program related to next generation telomerase inhibitors.

https://www.stonkmoon.com/news/GERN/1242cffb229cc72c9f1cc5f4ee5461f2
 

Gestern nach Börsenschluss mit -25% und heute deutlich im Plus....Was für eine Kurs-Verwerfung ,sieht man auch nicht jeden Tag  

muss mal jemand verstehen, aber gut, mir soll es recht sein.  

75 Mio. $ Offering

• 53,3 Mio. Aktien + warrants zu 1,05$
  

https://ir.geron.com/investors/press-releases/...arrants/default.aspx

Rational nachvollziehbar ist dieser Kursananstieg (nach Bekanntgabe dieses Offerings) jedenfalls nicht.

 

 

GERN's drug imetelstat called the Future Oncology. "Published by John Mascarenhas, MD and team on May 2, 2022.
Dr. Mascarenhas received research grant/funding from Incyte, Novartis, CTI BioPharma, Geron, PharmaEssentia, AbbVie, Bristol Myers Squibb, Celgene, Roche, Kartos, Promedior, and Merck in addition to many others. (Pay attention to big pharmas who are sponsoring the study)
The study designed to compare Imetelstat against two BAT; JAK inhibitors, ruxolitinib and fedratinib. An excellent study with no risk to patients.
Imetelstat vs. BAT, follow up visit after treatment ended. If progressive disease with BAT, patients were eligible for crossover to Imetelstat."
“They concluded that the study has the potential to change the treatment landscape in refractory MF and address a critical unmet need for disease-modifying therapies that will improve survival in this poor-prognosis patient population.”
(BAT is best available current treatments)  

 

"Aus wettbewerblicher Sicht ist es ein Hindernis und ein Nachteil für $GERN und seine Entwicklung von imetelstat."

https://twitter.com/adamfeuerstein/status/...cxt=HHwWgMC4wZ3mpoYsAAAA

 

Heute werden die Phase3 Daten der IMerge Studie diskutiert. Bei negativen Daten halte ich einen Kursrückgang von über 70% für möglich. Sollte die Daten positiv ausfallen, bin ich gespannt, ob und wie weit der Kurs dann anspringen würde. Um 14 Uhr startet der CC.
https://ir.geron.com/investors/press-releases/...Phase-3/default.aspx  

positive Studienergebnisse

https://ir.geron.com/investors/press-releases/...isk-MDS/default.aspx

 

 

Geron Corporation Announces Proposed Public Offering of Common Stock

...today announced that it intends to offer and sell $175 million of shares of its common stock in an underwritten public offering. All of the securities in the proposed offering are to be sold by Geron. Geron intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

https://finance.yahoo.com/news/...nces-proposed-public-211900778.html  

Das 175 Mio. $ Offering würgt den Kursanstieg natürlich ziemlich ab. Mal sehen zu welchem Preis je Aktie das Offering stattfinden soll.
https://ir.geron.com/investors/press-releases/...n-Stock/default.aspx
 

Die Anküdigung des Offerings bringt den Kurs unter Druck.  

Pricing

• 55,8 Mio. neue Aktien zu je 2,45$
• 25 Mio. warrants zu je 2,449$
  
• Volumen insgesamt 198 Mio. $
  

https://ir.geron.com/investors/press-releases/...arrants/default.aspx

 

Überlege nachzukaufen...da scheint irgendwas zu kommen  

 

Primary endpoint of 8-week transfusion independence (TI) significantly higher with imetelstat vs. placebo (P<0.001), with median TI duration approaching one year for imetelstat 8-week TI responders

Statistically significant and clinically meaningful efficacy results achieved across key MDS subgroups: ring sideroblast (RS) status, baseline transfusion burden and IPSS risk category

Safety results consistent with prior imetelstat clinical experience

Reduction in variant allele frequency (VAF) of genes commonly mutated in MDS and their correlation with clinical endpoints support disease-modifying potential of imetelstat

Data support NDA submission which is on track for June 2023 to support potential U.S. commercial launch in first half of 2024

https://finance.yahoo.com/news/...esentation-reporting-193000539.html  

 

150 Mio. $ Offering

• 42 Mio. neue Aktien zu je 3$
  

https://ir.geron.com/investors/press-releases/...arrants/default.aspx

 

FDA Zulassung für RYTELO

https://pharmaphorum.com/news/...brings-drug-market-fda-clears-rytelo